Navigation Links
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Date:11/2/2007

- Roche progresses R1626 into phase IIb study, called POLI 1 -

BOSTON, Nov. 2 /PRNewswire/ -- R1626, one of Roche's new investigational drugs for chronic hepatitis C virus (HCV) infection, has shown promising antiviral activity when given in combination with PEGASYS(R) (peginterferon alfa-2a) and COPEGUS(TM) (ribavirin), according to results being presented at the American Association for the Study of the Liver Disease (AASLD) meeting, being held in Boston, Nov. 2-6. After four weeks of treatment with this triple combination, the virus could no longer be detected in up to 81 percent of patients, with a mean decrease in viral load of 5.2 log10 from baseline. This is indicative of a robust virological response, and R1626 is being progressed into Phase IIb study as a result of these findings.

R1626 belongs to a class of antivirals called polymerase inhibitors, which are being investigated in combination with the current standard of care, pegylated interferon and ribavirin. The hope is that this combination will increase the number of patients who are able to be successfully treated for hepatitis C.

"The results from this Phase IIa study show that R1626 has a profound antiviral effect when used in combination with PEGASYS plus COPEGUS," said Dr. Paul Pockros, Scripps Clinic, San Diego, California, the lead investigator of the study. "This effect of R1626 in combination therapy, along with the lack of resistance observed to date, means that R1626 could be an exciting drug for patients with hepatitis C, if a safe and acceptable dosing regimen can be determined in future studies."

Antiviral Activity and Safety Results Being Presented at AASLD

The multicenter Phase IIa study enrolled patients with genotype 1 chronic HCV who have not previously received treatment. The objectives were to evaluate the four-week activity and safety of combining R1626 with PEGASYS alone or R1626 with PEGASYS plus COPEGUS in comparison to PEGASYS/COPEGUS,
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... -- UBM Medica US today announced the launch of ... information resource for neurologists and other healthcare providers to ... neurological disorders . The prevalence of ... access to dedicated information for healthcare providers who treat ... , 1 in 6 people are affected ...
(Date:7/23/2014)... , July 23, 2014 Research ... "Diagnostic Electrocardiograph (ECG) Market by Product, End-user & by ... to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... is segmented into three major segments, namely, holter monitor, ... market was valued at $3,683 million in 2013 and ...
(Date:7/23/2014)... 23, 2014 /PRNewswire-iReach/ -- The Centers for Medicare & ... Innovation Network-Quality Improvement Organization (QIN-QIO) contract to a partnership ... Effective August 1, WVMI will launch Quality Insights ... , Pennsylvania , Delaware ... Louisiana.  The Network will engage providers and the community ...
Breaking Medicine Technology:UBM Medica US Launches NeurologyTimes.com 2UBM Medica US Launches NeurologyTimes.com 3Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 2Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 3Announcing a New Regional Approach to Medicare Quality Improvement 2
... 20, 2012   Sysmex America, Inc., a global leader ... today announced its 200th placement of Sysmex WAM ... Laboratory.  Sysmex WAM is now connecting nearly 600 sites ... U.S. and Canada. Sysmex WAM plays a key role ...
... Assured Pharmacy (Pinksheets: APHY), a leading specialty pharmacy group ... present at Anda,s 2012 Supply Chain Symposium on Thursday, ... in Palm Beach Gardens, Florida.  Assured Pharmacy has been ... dispensing controlled substances at pharmacies.   Anda ...
Cached Medicine Technology:Sysmex America Achieves Clinical Laboratory Connectivity Milestone 2Assured Pharmacy to Present at Anda's 2012 Supply Chain Symposium 2Assured Pharmacy to Present at Anda's 2012 Supply Chain Symposium 3
(Date:7/23/2014)... The National Quality Forum’s (NQF) Board ... for a defined period that will assess the ... measures for sociodemographic factors, prior to making a ... can be socioeconomic, e.g., income, education, and occupation, ... Growing evidence shows that sociodemographic factors may ...
(Date:7/23/2014)... Recently, iFitDress.com, a professional company of women’s dresses and related ... party dresses . Aside from that, it has launched a ... to 63% off. , “We are excited to offer our ... all manufactured by trustworthy and experienced workers in the fashion ... is great to provide such a great opportunity for our ...
(Date:7/23/2014)... of Exeter has developed a simple, cheap and ... lung disease which attacks immune deficient individuals such ... , The lateral-flow device (LFD), created by Professor ... difficult to diagnose disease caused by the fungus ... aspergillosis is a leading cause of death in ...
(Date:7/23/2014)... July 23, 2014 A new study ... power morcellator ( http://www.injurybeacon.com/power-morcellator/ ) during minimally invasive ... throughout a woman’s body, Bernstein Liebhard LLP reports. The ... Journal of the American Medical Association, looked at 36,000 ... at 500 U.S. hospitals from 2006 to 2012. Ninety-nine ...
(Date:7/23/2014)... (NEW YORK, NY, July 24, 2014) If past ... New York State are about to get a lot ... Massachusetts, laws already on the books allowing NPs to ... contributions to patient care and better relationships with physicians ... to a study from Columbia University School of Nursing, ...
Breaking Medicine News(10 mins):Health News:NQF Board Approves Trial Period to Test Impact of Risk Adjustment of Performance Measures for Sociodemographic Factors 2Health News:Cheap 2014 Vintage Party Dresses From Professional Supplier iFitDress.com 2Health News:New device detects deadly lung disease 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 4Health News:New York law offers nurses more recognition, responsibility 2
... Henrico Doctors, Hospital is a full service acute care ... St. Mary,s Hospital. Early in 2008, Henrico,s administration noted ... St. Mary,s volume was increasing. After investigation, the problem ... and was compounding throughout the facility. Most notably, ...
... PORTLAND, Ore. Oregon Health & Science University and ... partner institutions across the Northwest, have received federal funding ... emerging or re-emerging infectious diseases that pose a serious ... the collaborative Pacific Northwest Regional Center for Excellence (PNWRCE) ...
... LLC has incorporated the NexCura(R) Cancer ProfilerTools from Thomson ... portal that provides information tools and clinically useful content ... their patients."This collaboration is another important step in helping ... Chris Yoo, Ph.D., president and CEO of MedTrust Online. ...
... Nichols Institute Diagnostics, Pleads Guilty to Felony Misbranding ... its subsidiary, Nichols Institute Diagnostics (NID), have entered ... to resolve criminal and civil claims concerning various ... marketed and sold to laboratories throughout the country ...
... April 15 TopBestPennyStocks.com is pleased to ... are interested in stocks on the move and in the news ... http://www.TopBestPennyStocks.com Today,s focused alerts include: ChinaCast Education (Nasdaq: ... VM ), Netflix Inc. (Nasdaq: NFLX ), Pfizer Inc. ...
... in minimally invasive surgical techniques -- most notably, ... common surgical option across the United States for ... , A newer, third option is a hybrid ... safe and effective and compares favorably with standard ...
Cached Medicine News:Health News:Compirion and Henrico Doctors Hospital Team Up to Improve Quality of Care 2Health News:Compirion and Henrico Doctors Hospital Team Up to Improve Quality of Care 3Health News:Compirion and Henrico Doctors Hospital Team Up to Improve Quality of Care 4Health News:Compirion and Henrico Doctors Hospital Team Up to Improve Quality of Care 5Health News:OHSU scientists partner with others to form center aimed at combating infectious diseases 2Health News:OHSU scientists partner with others to form center aimed at combating infectious diseases 3Health News:MedTrust Online to Provide NexCura Cancer Profiler Tools from Thomson Reuters to Oncologists 2Health News:Quest Diagnostics to Pay U.S. $302 Million to Resolve Allegations That a Subsidiary Sold Misbranded Test Kits 2Health News:Quest Diagnostics to Pay U.S. $302 Million to Resolve Allegations That a Subsidiary Sold Misbranded Test Kits 3Health News:Quest Diagnostics to Pay U.S. $302 Million to Resolve Allegations That a Subsidiary Sold Misbranded Test Kits 4Health News:TopBestPennyStocks.com Issues Technical Trade Alerts on Hot Stocks in the Market Today: CAST, VM, NFLX, PFE, AA, & COF 2Health News:Helping hand of hybrid surgery benefits colorectal patients 2
The reliable and easy-to-use 3900/P pulse oximeter is now more advanced - featuring TruTrak+ technology, the proprietary clinical motion algorithm from Datex+-Ohmeda....
... Digital Pulse Oximeter monitors SpO2, ... It is designed to provide ... patients. The device rejects spontaneous ... the operator of excess artifacts ...
... The 8600FO is designed to ... MRI users for patient safety ... Fiber Optic Sensors and Cables ... is eliminated, as well as ...
... The 8600 Series Tabletop/Portable ... simple universal tool for patient ... continuous monitoring, the 8600 has ... professionals worldwide and is recognized ...
Medicine Products: